Phase 3 Pulmonary Arterial Hypertension Clinical Trials
5 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–5 of 5 trials
Recruiting
Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC815 enrolled93 locationsNCT07218029
Recruiting
Phase 3
Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH
Pulmonary Arterial Hypertension
AOP Orphan Pharmaceuticals AG20 enrolled5 locationsNCT06350032
Recruiting
Phase 3
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
Pulmonary Arterial Hypertension
University of Arizona20 enrolled1 locationNCT04062565
Recruiting
Phase 2Phase 3
Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation260 enrolled1 locationNCT06683040
Terminated
Phase 3
Scleroderma-Pulmonary Arterial Hypertension Intervention with Apixaban: The SPHInX Study
Pulmonary Arterial HypertensionSystemic Sclerosis
St Vincent's Hospital Melbourne Pty Ltd170 enrolled14 locationsACTRN12614000418673